Ridgeback Biotherapeutics LP
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.ridgebackbio.com
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
- Conditions
- Ebola Virus Disease
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Ridgeback Biotherapeutics, LP
- Registration Number
- NCT05067166
- Locations
- 🇸🇱
University of Sierra Leone Teaching Hospital Complex, Freetown, Sierra Leone
🇨🇩Institut National de Recherche Biomedical, Beni, North Kivu, Congo, The Democratic Republic of the
🇨🇩Institut National de Recherche Biomédicale, Butembo, North Kivu, Congo, The Democratic Republic of the
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
Phase 2
Completed
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- Drug: Molnupiravir 200 mgDrug: Molnupiravir 400 mgDrug: Molnupiravir 800 mgDrug: Placebo (PBO)
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Ridgeback Biotherapeutics, LP
- Target Recruit Count
- 204
- Registration Number
- NCT04405570
- Locations
- 🇺🇸
Southern California Emergency Medicine, Yucaipa, California, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸FOMAT Medical Research, Oxnard, California, United States
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Ridgeback Biotherapeutics, LP
- Target Recruit Count
- 71
- Registration Number
- NCT04405739
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Cook County Hospital, Chicago, Illinois, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Ridgeback Biotherapeutics, LP
- Target Recruit Count
- 130
- Registration Number
- NCT04392219
- Locations
- 🇬🇧
Covance Leeds Clinical Research Unit, Leeds, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath